© iStock An experimental Alzheimer’s drug that moderately slows cognitive decline was approved by the Food and Drug Administration (FDA) on Friday. The drug, called lecanemab, was granted conditional approval based on a study finding it reduced levels of a protein called amyloid from the brains of people with early-stage Alzheimer’s. FDA’s decision comes after […]

The post Not a Cure: New Alzheimer’s Drug Given Green Light  appeared first on The St Kitts Nevis Observer.